Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.55 |
| ▸ | PDE8A | O60658 | 3/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141496 | 0.89 | PDE7A (0.54) | PDE7APDE7BPDE8A | |
| SCHEMBL100195 | 0.89 | PDE7A (0.60) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL100537 | 0.89 | PDE7A (0.60) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL101022 | 0.86 | PDE7A (0.51) | PDE7APDE7BPDE8A | |
| SCHEMBL101209 | 0.86 | PDE7A (0.59) | PDE7APDE7BPDE8AS1PR1OPRM1 | |
| SCHEMBL101040 | 0.86 | PDE7A (0.66) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100406 | 0.86 | PDE7A (0.53) | PDE7APDE7BPDE8A | |
| SCHEMBL101041 | 0.85 | PDE7A (0.57) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL101053 | 0.85 | PDE7A (0.63) | PDE7APDE7BPDE8A | |
| SCHEMBL30837809 | 0.84 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.